Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetazolamide-associated aplastic anaemia.

M Keisu1, B E Wiholm, A Ost

  • 1Department of Drugs, National Board of Health and Welfare, Uppsala, Sweden.

Journal of Internal Medicine
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Male reproductive health and intergenerational metabolic responses from a small RNA perspective.

Journal of internal medicine·2020
Same author

A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

Leukemia & lymphoma·2016
Same author

Nitric oxide and endothelin-1 release after one-lung ventilation during thoracoabdominal esophagectomy.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2012
Same author

Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission.

Alimentary pharmacology & therapeutics·2011
Same author

Evidence for immunosurveillance in intestinal premalignant lesions.

Scandinavian journal of immunology·2010
Same author

Anorectal function in patients with collagenous colitis in active and clinically quiescent phase, in comparison with healthy controls.

Neurogastroenterology and motility·2010
Same journal

Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population-based registry study.

Journal of internal medicine·2026
Same journal

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same journal

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same journal

Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.

Journal of internal medicine·2026
Same journal

Multicenter validation of a severity index model for predicting postoperative acute kidney injury.

Journal of internal medicine·2026
Same journal

The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.

Journal of internal medicine·2026
See all related articles

Acetazolamide treatment significantly increases the risk of developing aplastic anaemia, a serious blood disorder. This study found a 13-fold higher risk, with most patients dying shortly after diagnosis.

Area of Science:

  • Pharmacovigilance
  • Hematology
  • Drug Safety

Background:

  • Acetazolamide is a carbonic anhydrase inhibitor used for various medical conditions.
  • Aplastic anaemia is a rare but life-threatening condition where the bone marrow fails to produce enough blood cells.

Purpose of the Study:

  • To investigate the potential association between acetazolamide use and the occurrence of aplastic anaemia.
  • To quantify the risk of developing aplastic anaemia in patients treated with acetazolamide.

Main Methods:

  • Retrospective analysis of reported cases in Sweden over 17 years.
  • Calculation of relative risk and incidence rates for acetazolamide-associated aplastic anaemia.

Main Results:

  • Eleven cases of aplastic anaemia linked to acetazolamide were identified.

Related Experiment Videos

  • The median patient age was 71 years, with a median treatment duration of 3 months.
  • A relative risk of 13.3 for aplastic anaemia was observed in acetazolamide users.
  • Ten out of eleven patients died within 8 weeks of diagnosis.

    • Conclusions:

    • Acetazolamide treatment is strongly associated with a substantial increase in the risk of aplastic anaemia.
    • The findings highlight a critical safety concern requiring further investigation and clinical vigilance.